4.2 Review

Long Noncoding RNA LIFR-AS1: A New Player in Human Cancers

Journal

BIOMED RESEARCH INTERNATIONAL
Volume 2022, Issue -, Pages -

Publisher

HINDAWI LTD
DOI: 10.1155/2022/1590815

Keywords

-

Funding

  1. Natural Science Foundation of Liaoning Province, China [2019-ZD-0772]
  2. National Natural Science Foundation of China [81471809, 81971639]

Ask authors/readers for more resources

LIFR-AS1 is a lncRNA transcribed in an antisense manner from the LIFR gene on human chromosome, and it plays a role in tumor growth, migration, invasion, apoptosis, and drug resistance through various mechanisms. It has the potential to serve as a biomarker and therapeutic target for different types of human cancers.
Emerging evidence has indicated that aberrantly expressed long noncoding RNAs (lncRNAs) play a vital role in various biological processes associated with tumorigenesis. Leukemia inhibitory factor receptor antisense RNA1 (LIFR-AS1) is a recently identified lncRNA transcribed in an antisense manner from the LIFR gene located on human chromosome 5p13.1. LIFR-AS1 regulates tumor proliferation, migration, invasion, apoptosis, and drug resistance through different mechanisms. Its expression level is related to the clinicopathological characteristics of tumors and plays a key role in tumor occurrence and development. In this review, we summarize the role of LIFR-AS1 in the development and progression of different cancers and highlight the potential for LIFR-AS1 to serve as a biomarker and therapeutic target for a variety of human cancers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available